HC Wainwright set a $9.00 target price on Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts have also recently weighed in on APTO. Zacks Investment Research raised shares of Aptose Biosciences from a hold rating to a buy rating and set a $2.50 price target on the stock in a research report on Monday, November 12th. B. Riley started coverage on shares of Aptose Biosciences in a research report on Friday, November 16th. They set a buy rating and a $5.00 price target on the stock. Finally, Roth Capital reissued a buy rating on shares of Aptose Biosciences in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $5.63.
Shares of APTO stock opened at $2.26 on Thursday. Aptose Biosciences has a 52-week low of $1.69 and a 52-week high of $4.55.
Several hedge funds and other institutional investors have recently made changes to their positions in APTO. Citadel Advisors LLC acquired a new stake in shares of Aptose Biosciences during the third quarter worth $125,000. Renaissance Technologies LLC raised its holdings in shares of Aptose Biosciences by 1,130.9% during the third quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after acquiring an additional 168,501 shares during the period. Finally, DRW Securities LLC raised its holdings in shares of Aptose Biosciences by 519.5% during the second quarter. DRW Securities LLC now owns 123,900 shares of the biotechnology company’s stock worth $488,000 after acquiring an additional 103,900 shares during the period. 3.28% of the stock is currently owned by institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: What Factors Can Affect Return on Equity?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.